Novo Nordisk shares jump up on latest weight loss trial results
People treated with amycretin lost up to 22% of their body weight after 36 weeks
Novo
since
auto-detected in 457 stories
3 months ago
4 months ago
Novo Nordisk’s drug stumble leaves it suddenly much slimmer
Market will never be winner takes all given that different patients will have different requirements
Novo Nordisk shares tumble as data on weight-loss drug trial disappoints
Obesity treatment CagriSema misses goal of 25% reduction in body weight
The battle over the trillion-dollar weight-loss bonanza
Novo Nordisk and Eli Lilly are making blockbuster drugs. Can they maintain their lead?
Competition will make weight-loss drugs better, cheaper and bigger
Novo Nordisk and Eli Lilly face a growing number of challengers
|← first ← previous page 5 of 5